EVFM

Evofem Biosciences Inc

EVFM, USA

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

https://www.evofem.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EVFM
stock
EVFM

Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals TipRanks

Read more →
EVFM
stock
EVFM

Evofem Announces Voting Results from Special Meeting of Stockholders Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$225

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.02

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.39 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.17 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

6.79 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 0.00% of the total shares of Evofem Biosciences Inc

1.

NT Quality Small Cap Core

(0.0001%)

since

2023/03/31

2.

NT Quality SCC US Fund - L

(0.0001%)

since

2023/03/31

3.

Laffer Tengler Investments, Inc.

(0%)

since

2022/12/31

4.

CLEAR STREET LLC

(0%)

since

2022/12/31

5.

IFP Advisors, LLC

(0%)

since

2022/12/31

6.

Activest Wealth Management

(0%)

since

2022/12/31

7.

Barclays PLC

(0%)

since

2022/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.02

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Moderate Quality(4)
Value
Overpriced(1)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.